• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:邓艳婷,谢焯华,邓家升,方怡镔,张心如,陈洁怡,叶晓雪,周至品.转录组学与代谢组学在中药防治肝纤维化研究中的应用进展[J].药学研究,2026,45(5):562-569,595[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1528次   下载 728次 本文二维码信息
码上扫一扫!
转录组学与代谢组学在中药防治肝纤维化研究中的应用进展
邓艳婷1,谢焯华1,邓家升1,方怡镔2,张心如2,陈洁怡2,叶晓雪3,周至品3
字体:加大+|默认|缩小-
(1.广西中医药大学药学院,广西 南宁 530001;2.广西医科大学药学院,广西 南宁 530021;3.广西医科大学附属柳州市人民医院,广西 柳州 545006)
摘要:
肝纤维化是慢性肝病进展至肝硬化和肝癌的关键可逆阶段,而当前临床治疗手段仍然十分有限。中医药凭借其多成分、多靶点、整体调节的特点,在防治肝纤维化方面显示出巨大潜力,然而其复杂的作用机制尚不明确。近年来,转录组学、代谢组学技术的发展,为揭示中药多靶点作用机制提供了不同视角,其全面性、整体性和系统性特点,与中医药的“整体思想”“辨证论治”契合,弥补了单个靶点、通路解释中药“整体调控”的局限性。本文综述了转录组学、代谢组学及联合应用在中药防治肝纤维化中的应用,以期为中药抗肝纤维化的研究与新药研发提供理论依据和新的策略。
关键词:  转录组学  代谢组学  中药  肝纤维化  研究进展
DOI:10.13506/j.cnki.jpr.2026.05.012
基金项目:广西中医药管理局自筹经费科研课题项目(No.GXZYB20230522)
收稿日期:2025-07-29   修回日期:2025-09-26   出版日期:2026-05-29
Progress in the application of transcriptomics and metabolomics in the study of traditional Chinese medicine prevention and treatment of liver fibrosis
DENG Yanting1,XIE Zhuohua1,DENG Jiasheng1,FANG Yibin2,ZHANG Xinru2,CHEN Jeiyi2,YE Xiaoxue3,ZHOU Zhipin3
(1. Pharmaceutical College, Guangxi University of Chinese Medicine, Nanning 530001, China; 2. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China; 3. Liuzhou People′s Hospital Affiliated to Guangxi Medical University, Liuzhou 545006, China)
Abstract:
Liver fibrosis is a critical reversible stage in the progression of chronic liver disease to cirrhosis and liver cancer, yet current clinical treatment options remain highly limited. Traditional Chinese medicine (TCM), with its multi-component, multi-target, and holistic regulatory characteristics, has demonstrated significant potential in preventing and treating liver fibrosis. However, its complex mechanisms of action are still not fully understood. In recent years, advances in transcriptomics and metabolomics have provided new perspectives for elucidating the multi-target mechanisms of TCM. The comprehensive, holistic, and systematic nature of these omics technologies aligns with the “holistic philosophy” and “treatment based on syndrome differentiation” principles of TCM, thereby overcoming the limitations of single-target or single-pathway explanations for the “overall regulation” of TCM. This review summarizes the applications of transcriptomics, metabolomics, and their integrated use in TCM for the prevention and treatment of liver fibrosis, aiming to provide a theoretical basis and novel strategies for research and drug development in this field.
Key words:  Transcriptomics  Metabolomics  Traditional Chinese medicine  Liver fibrosis  Research progress
今日访问量:2274    总访问量:55338616
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司